MASHINIi

FibroBiologics, Inc..

FBLG.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

FibroBiologics, Inc. is a biotechnology company focused on the development of fibroblast-based therapies for chronic diseases. The company engineers human fibroblasts to secrete therapeutic proteins, aiming to address unmet needs in areas such as wound healing, cancer, and degenerative diseases. The...Show More

Ethical Profile

Mixed.

Not enough information to create an ethical profile.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals-60
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech10
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

0

No evidence available to assess FibroBiologics, Inc. on Better Health for All.

Fair Money & Economic Opportunity

0

No evidence available to assess FibroBiologics, Inc. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No relevant data was found in the provided article to assess FBLG.US against the Fair Pay & Worker Respect ethical value.

1
The article explicitly states it focuses on a different company (Advantage Business) and contains no data for FBLG.US or the requested metrics.
2

Fair Trade & Ethical Sourcing

0

No evidence available to assess FibroBiologics, Inc. on Fair Trade & Ethical Sourcing.

Honest & Fair Business

0

The company's board of directors has six independent members out of a total of seven, meaning approximately 85.7% are conflict-free.

1
However, the sole non-independent director, Pete O’Heeron, holds 100% of the Series C Preferred Stock, which carries 13,000 votes per share, giving the board 32,500,000 votes (46.1% of total votes) via an irrevocable proxy.
2
This proxy, however, does not allow the board to vote on proposals affecting Mr. O’Heeron's rights regarding the Series C Preferred Stock.
3
The company has adopted a Code of Ethics and Business Conduct for all directors, officers, and employees, and has insider trading policies.
4
A material weakness in internal control over financial reporting due to a lack of segregation of duties was identified.
5
Additionally, some Section 16a reports were filed late in 2024 due to administrative error and oversight.
6

Kind to Animals

-60

FibroBiologics conducts extensive preclinical animal studies for its product candidates, including using diabetic mice, rabbit models, psoriasis mouse models, EAE animal models, and xenografted melanoma mouse models.

1
For CybroCell™, two animal studies were completed in rabbit models, involving 16 animals in the first study and 38 animals in the second.
2
The company uses in vitro studies in addition to in vivo animal studies,
3
and is developing fibroblast spheroids, engineered organoids, and Bone Marrow Organoids as part of its research platform.
4
However, the evidence does not indicate a formal policy to reduce or replace animal testing, nor does it provide transparent reduction goals for animal testing volume.

No War, No Weapons

0

The company is a clinical-stage biotechnology firm focused on fibroblast-based therapies and is explicitly stated as not being a defense contractor, indicating no defense or arms-related activities in its core business.

1
There is no evidence of the company developing or selling dual-use products.
2
While the company has adopted a general Code of Ethics and Business Conduct,
3
there is no specific information provided regarding codified ethical 'red lines' that ban involvement in controversial weapons or military supply chains,
4
which is not applicable given its core business.

Planet-Friendly Business

0

No evidence was found in the provided articles to assess FibroBiologics, Inc. against any of the Planet-Friendly Business KPIs. The articles focus on general biopharmaceutical industry news, research and development of therapies, and a counterproposal to research overhead cuts, none of which contain specific data points related to environmental performance, targets, or initiatives for FBLG.US.

1

Respect for Cultures & Communities

0

No evidence available to assess FibroBiologics, Inc. on Respect for Cultures & Communities.

Safe & Smart Tech

10

The company states that no personal information is shared, indicating strong preventative measures against unauthorized data use.

1
IP addresses are used to diagnose server problems, administer the website, and gather broad demographic information, and are stored as a partial identifier.
2
Cookies are utilized to deliver content specific to user interests and to save passwords when applicable.
3
The privacy policy may be amended periodically.
4

Zero Waste & Sustainable Products

0

No specific, concrete data points were found for FBLG.US regarding any of the 'Zero Waste & Sustainable Products' KPIs. The articles provided general information about sustainability in the biotech industry, examples from other companies, or focused on FBLG.US's financial and clinical trial updates, but did not offer measurable evidence for FBLG.US's waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability scores, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.

1

Own FibroBiologics, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.